Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Xenetic Biosciences, Inc. (XBIO) had Consolidated Net Income/Loss of $-0.46M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.81M |
|
$-0.46M |
|
-- |
|
$0.81M |
|
$1.31M |
|
$-0.50M |
|
$0.05M |
|
$-0.46M |
|
$-0.46M |
|
$-0.46M |
|
$-0.46M |
|
|
Consolidated Net Income/Loss |
$-0.46M |
$-0.46M |
|
$-0.50M |
|
$-0.50M |
|
2.29M |
|
2.29M |
|
$-0.20 |
|
$-0.20 |
|
| Balance Sheet Financials | |
$7.60M |
|
-- |
|
$0.31M |
|
$7.91M |
|
$0.96M |
|
-- |
|
-- |
|
$0.96M |
|
$6.95M |
|
$6.95M |
|
$6.95M |
|
2.29M |
|
| Cash Flow Statement Financials | |
$-0.54M |
|
-- |
|
-- |
|
$7.88M |
|
$7.35M |
|
$-0.54M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.93 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-62.23% |
|
-62.23% |
|
-- |
|
-56.56% |
|
-56.56% |
|
$-0.54M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
-- |
|
-- |
|
-6.57% |
|
-6.57% |
|
-5.77% |
|
-6.57% |
|
$3.03 |
|
$-0.23 |
|
$-0.23 |
|